Our
Approach

Science

LEVERAGING THE PHYSIOLOGICAL KETONE SYSTEM TO PROVIDE FUEL FOR THE BRAIN IS A PROMISING APPROACH TO ADDRESSING DEFICIENT GLUCOSE METABOLISM THAT IS CHARACTERISTIC OF NUMEROUS NEUROLOGICAL CONDITIONS.

Science

The brain determines how we think, what we do, who we are. As we age, changes to our brain inevitably occur, including death of neurons, loss of synapses, brain shrinkage and cognitive impairment. In the most extreme cases, cognitive impairment is due to neurodegenerative processes, including those seen in Alzheimer’s disease and other dementias. Cerecin is committed to the maintenance of brain function in health and disease.

decorative molecules

Our Method Of Action

TRICAPRILIN: THE INDUCTION OF KETOSIS

Leveraging the physiological ketone system to provide fuel for the brain is a promising approach to addressing deficient glucose metabolism that is characteristic of numerous neurological conditions.

We produce ketone bodies, which in turn circulate through our system

These Ketone bodies can cross our blood brain barrier, due to its small molecules. This mechanism addresses deficient glucose metabolism that is characteristic of numerous neurological conditions.

decorative molecules

THE KETOSIS STRATEGY IN ALZHEIMER'S DISEASE

Cerecin’s investigational product, tricaprilin, is a highly purified proprietary, oral formulation of a medium chain triglyceride, which has been designed to induce ketosis and thereby improve mitochondrial metabolism.

An early Phase 2a clinical study was conducted at an academic site in the US. In this single-dose crossover design, an improvement in cognition was observed in patients who do not carry the APOE4 gene, 90 minutes after single dose administration. Furthermore, this improvement in cognition was shown to correlate with increased levels of ketones. 1
Subsequently, a Phase 2b multi-center, double blind, placebo-controlled 90-day study was conducted in subjects with mild to moderate Alzheimer’s disease in the US. In the prespecified APOE4 negative population, a statistically significant change vs placebo was seen.2

View our Pipeline

PRE-SPECIFIED SUB-GROUP ANALYSIS IN 55 APOE4 (-) PATIENTS

  1. Reger et al. Neurobiology of Aging ; 2004; 25:311
  2. Henderson ST et al. Nutr Metab (Lond). 2009;6:31.
en_USEnglish (United States)
ko_KRKorean en_USEnglish (United States)